ractigen, Author at Ractigen Therapeutics

Presentations RAG-01 Presentation

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Event: 2024 Oligonucleotide Therapeutics Society Meeting (Montreal) View Abstract

ractigenOctober 11, 2024

Company News RAG-17

Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial

NANTONG and SUZHOU, China, Sep.10, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to…

ractigenSeptember 10, 2024

Company News

Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

JIANGSU, China, August 22, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…

ractigenAugust 22, 2024

Company News

Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

JIANGSU, China, July 25, 2024 -- Ractigen Therapeutics, a pioneering developer of small activating RNA…

ractigenJuly 25, 2024

Company News RAG-01

Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy

SUZHOU, China, May 21, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…

ractigenMay 21, 2024

Company News RAG-17

Ractigen Therapeutics Receives IND Approval from China’s NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients

JIANGSU, CHINA (May 15, 2024) – Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing…

ractigenMay 15, 2024

Company News RAG-01

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…

ractigenApril 26, 2024

Company News RAG-01

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…

ractigenApril 3, 2024

Presentations

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2024 TIDES Asia Conference (Tokyo Japan) View Poster

ractigenMarch 21, 2024

Company News

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

Suzhou, China – January 29, 2024 – Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the…

ractigenJanuary 29, 2024

ractigen

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial

Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

Ractigen Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy

Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy

Ractigen Therapeutics Receives IND Approval from China’s NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

Join Us

CONTACT US

Follow Us